FFA
MRNA icon

Fairfield Financial Advisors’s Moderna MRNA Stock Holding History

Fairfield Financial Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$416 – 144
2024
Q4 		$416 Hold
10
– – ﹤0.01% 255
2024
Q3 		$668 Sell
10
-35
-78% -$3.21K ﹤0.01% 281
2024
Q2 		$5.34K Buy
+45
New +$5.7K ﹤0.01% 239
2023
Q4 		$68.5K Sell
689
-609
-47% -$51.2K 0.03% 119
2023
Q3 		$134K Sell
1,298
-635
-33% -$70.8K 0.06% 85
2023
Q2 		$235K Sell
1,933
-498
-20% -$66.4K 0.09% 64
2023
Q1 		$358K Sell
2,431
-132
-5% -$21.8K 0.16% 54
2022
Q4 		$460K Sell
2,563
-280
-10% -$45.8K 0.21% 44
2022
Q3 		$336K Sell
2,843
-42
-1% -$6.37K 0.16% 48
2022
Q2 		$412K Sell
2,885
-1,098
-28% -$157K 0.19% 44
2022
Q1 		$686K Buy
+3,983
New +$671K 0.25% 43

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fairfield Financial Advisors's MRNA Position: Q1 2025 in Review

Fairfield Financial Advisors sold out of Moderna (MRNA) in Q1 2025, closing a stake of 10 shares — an estimated $416 sold.

Fairfield Financial Advisors first reported a position in MRNA in Q1 2022 and held it in 11 quarters. The position peaked at $686K in Q1 2022. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Fairfield Financial Advisors reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Fairfield Financial Advisors sold 10 Moderna shares in Q1 2025, an estimated $416.
  • Fairfield Financial Advisors first reported a position in Moderna in Q1 2022 and held it in 11 quarters.
  • Fairfield Financial Advisors's Moderna position peaked at $686K in Q1 2022.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Fairfield Financial Advisors's 13F filing for Q1 2025, filed 9 May 2025.